Farmakogenetika
Farmakogenetika se bavi genetičkim razlikama u metaboličkim putemiva koji utiču na individualne response na lekove, u pogledu terapeutskog dejstva i nuspojava.[1]
U onkologiji se farmakogenetika tradicionalno odnosi na gonocitne mutacije (e.g., jednonukleotidne polimorfizame gena koji kodiraju enzime jetre odgovorne za uklanjanje lekova i farmakokinetiku), dok se farmakogenomika odnosi na somatske mutacije u tumorskoj DNK koji uzrokuju promene u responsu na lek (e.g., KRAS mutacije kod pacijenata tretiranih sa anti-Her1 biološkim agensima).[2]
Reference
- ↑ Klotz, U. (2007). „The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.”. Clin Pharmacokinet 46 (4): 271–9. PMID 17375979.
- ↑ Roses AD (June 2000). „Pharmacogenetics and the practice of medicine”. Nature 405 (6788): 857–65. DOI:10.1038/35015728. PMID 10866212.
Literatura
- Abbott A (October 2003). „With your genes? Take one of these, three times a day”. Nature 425 (6960): 760–2. DOI:10.1038/425760a. PMID 14574377.
- Evans WE, McLeod HL (February 2003). „Pharmacogenomics – drug disposition, drug targets, and side effects”. N. Engl. J. Med. 348 (6): 538–49. DOI:10.1056/NEJMra020526. PMID 12571262.
- Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W (November 2001). „Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review”. JAMA 286 (18): 2270–9. DOI:10.1001/jama.286.18.2270. PMID 11710893.
- Weinshilboum R; Collins, Francis S.; Weinshilboum, Richard (February 2003). „Inheritance and drug response”. N. Engl. J. Med. 348 (6): 529–37. DOI:10.1056/NEJMra020021. PMID 12571261.
Povezano
- Farmakogenomika
- Hemogenomika
- Strukturna genomika
Spoljašnje veze
- Pharmacogenomics: Medicine and the new genetics from the Human Genome Project
- Pharmacogenomics in Drug Discovery and Development, a book on pharmacogenomics, diseases, personalized medicine, and therapeutics
- The Pharmacogenomics Journal
- PharmGKB The Pharmacogenetics and Pharmacogenomics Knowledge Base, a free online tool for Pharmacogenetics research
- p
- r
- u
Početna doza • Volumen distribucije (Inicijalni) • Stopa infuzije
Pregrada • Bioekvivalentnost • Biodostupnost
Početak dejstva • Biološki polu-život • Vezivanje za proteine plazme
Terapeutski indeks (LD50/ED50)Antagonist: Konkurentni antagonist • Ireverzibilni antagonist • Fiziološki antagonist
Drugo: Vezivanje • Afinitet • Selektivnost vezivanja • Funkcionalna selektivnost